<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-201
Date of Submission: 2025-03-12

This report was submitted by a Other Healthcare Professional from Booker-Mccall Medical Center concerning patient ANON-PX-6833. The subject is an adult female with a significant medical history including seasonal allergies, chronic kidney disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Sertraline administered via the Subcutaneous route at a dosage of 190mg, initiated on 2024-12-13 for Major depressive disorder and discontinued on 2025-02-25; Ibuprofen (NSAID) administered via the Oral route at a dosage of 286mg, initiated on 2024-12-13 for Pain and inflammation and discontinued on 2025-02-25.

On approximately 2025-02-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Pruritus. The Anaphylaxis was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed model and advised inside. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Space box this. Include against bag condition available. Truth always sure artist.</data>
report_id: ADR-2025-201
report_date: '2025-03-12'
patient_details:
  patient_id: ANON-PX-6833
  gender: Female
  relevant_history:
  - seasonal allergies
  - chronic kidney disease
  - anxiety
suspected_drugs:
- drug_name: Sertraline
  dosage: 190mg
  route_of_administration: Subcutaneous
  start_date: '2024-12-13'
  indication_for_use: Major depressive disorder
  end_date: '2025-02-25'
- drug_name: Ibuprofen
  dosage: 286mg
  route_of_administration: Oral
  start_date: '2024-12-13'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
  end_date: '2025-02-25'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2025-02-13'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed model and advised inside.
- symptom_name: Pruritus
  onset_date: '2025-02-13'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 5
reporting_facility: Booker-Mccall Medical Center
reporter_type: Other Healthcare Professional
notes: Space box this. Include against bag condition available. Truth always sure
  artist.
